Search

Your search keyword '"Rosenbaum, Cara A."' showing total 244 results
Start Over Author "Rosenbaum, Cara A."
244 results on '"Rosenbaum, Cara A."'

1. Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma

Author

Mejia Saldarriaga, Mateo, Pan, Darren, Unkenholz, Caitlin, Mouhieddine, Tarek H., Velez-Hernandez, Juan Esteban, Engles, Katherine, Fein, Joshua A., Monge, Jorge, Rosenbaum, Cara, Pearse, Roger, Jayabalan, David, Gordillo, Christian, Chan, Hei Ton, Yamshon, Samuel, Thibaud, Santiago, Mapara, Markus, Inghirami, Giorgio, Lentzsch, Suzanne, Reshef, Ran, Rossi, Adriana, Parekh, Samir, Jagannath, Sundar, Richard, Shambavi, Niesvizky, Ruben, and Bustoros, Mark

Published
2024
Full Text
View/download PDF

2. Publisher Correction: A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements

Author

Kimmerling, Robert J., Stevens, Mark M., Olcum, Selim, Minnah, Anthony, Vacha, Madeleine, LaBella, Rachel, Ferri, Matthew, Wasserman, Steven C., Fujii, Juanita, Shaheen, Zayna, Sundaresan, Srividya, Ribadeneyra, Drew, Jayabalan, David S., Agte, Sarita, Aleman, Adolfo, Criscitiello, Joseph A., Niesvizky, Ruben, Luskin, Marlise R., Parekh, Samir, Rosenbaum, Cara A., Tamrazi, Anobel, and Reid, Clifford A.

Published
2023
Full Text
View/download PDF

3. Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy.

Author

Sohani, Aliyah, Maurer, Matthew, Giri, Sharmila, Pitcher, Brandelyn, Chadburn, Amy, Said, Jonathan, Bartlett, Nancy, Czuczman, Myron, Martin, Peter, Rosenbaum, Cara, Jung, Sin-Ho, Leonard, John, Cheson, Bruce, and Hsi, Eric

Subjects
Adult, Aged, Aged, 80 and over, Antigens, CD20, Antineoplastic Agents, Immunological, Biomarkers, Tumor, Clinical Trials as Topic, Disease Progression, Female, Humans, Immunohistochemistry, Ki-67 Antigen, Lymphoma, Follicular, Male, Middle Aged, Neoplasm Staging, Neprilysin, Prospective Studies, Proto-Oncogene Proteins c-bcl-6, Recurrence, Risk Assessment, Risk Factors, Rituximab, Time Factors, Treatment Outcome, Tumor Microenvironment, United States, Young Adult
Abstract

Follicular lymphoma (FL) is an indolent B-cell neoplasm of germinal center origin. Standard treatment regimens consist of anti-CD20 therapy with or without chemotherapy. While high response rates to initial therapy are common, patients ultimately relapse or have progressive disease. Clinical risk factors such as the Follicular Lymphoma International Prognostic Index (FLIPI) have been identified, but there is a need for prognostic and predictive biomarkers. We studied markers of lymphoma cells and tumor microenvironment by immunohistochemistry in tissue samples from patients enrolled in 1 of 4 phase 2 trials of anti-CD20-based biological therapy for previously untreated grades 1 to 2 or 3A FL. Results were correlated with progression-free survival (PFS) and PFS status at 24 months. The 4 trials included 238 patients (51.1% male, median age: 55 y) with stage III, IV, or bulky stage II disease. By FLIPI, 24.6% had low-risk, 56.8% had intermediate-risk, and 18.6% had high-risk disease. The outcome differed significantly for patients treated with lenalidomide and rituximab (CALGB 50803) compared with the other 3 trials (median: PFS not reached vs. 3.0 y, hazard ratio=3.47, 95% confidence interval: 2.11-5.72); therefore, data were stratified by clinical trial (CALGB 50803 vs. all others) and adjusted for FLIPI risk group. Among 154 patients with available tissue, interfollicular BCL6 positivity, interfollicular CD10 positivity, and elevated Ki67 proliferation index ≥30% within neoplastic follicles were each associated with inferior PFS and a high risk of the early event by PFS status at 24 months. We identify promising biomarkers for FL risk stratification that warrant further validation in phase 3 trials.

Published
2021

4. Cellular Mass Response to Therapy Correlates With Clinical Response for a Range of Malignancies

Author

Stevens, Mark M., Kimmerling, Robert J., Olcum, Selim, Vacha, Madeleine, LaBella, Rachel, Minnah, Anthony, Katsis, Katelin, Fujii, Juanita, Shaheen, Zayna, Sundaresan, Srividya, Criscitiello, Joseph, Niesvizky, Ruben, Raje, Noopur, Branagan, Andrew, Krishnan, Amrita, Jagannath, Sundar, Parekh, Samir, Sperling, Adam S., Rosenbaum, Cara A., Munshi, Nikhil, Luskin, Marlise R., Tamrazi, Anobel, and Reid, Clifford A.

Published
2024
Full Text
View/download PDF

5. Correction: COVID-19 Infections and Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers.

Author

Hultcrantz, Malin, Richter, Joshua, Rosenbaum, Cara, Patel, Dhwani, Smith, Eric, Korde, Neha, Lu, Sydney, Mailankody, Sham, Shah, Urvi, Lesokhin, Alexander, Hassoun, Hani, Tan, Carlyn, Maura, Francesco, Derkach, Andriy, Diamond, Benjamin, Rossi, Adriana, Pearse, Roger, Madduri, Deepu, Chari, Ajai, Kaminetzky, David, Braunstein, Marc, Gordillo, Christian, Reshef, Ran, Taur, Ying, Davies, Faith, Jagannath, Sundar, Niesvizky, Ruben, Lentzsch, Suzanne, Morgan, Gareth, and Landgren, Ola

Abstract

[This corrects the article DOI: 10.1158/2643-3230.BCD-20-0102.].

Published
2020

6. COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers.

Author

Hultcrantz, Malin, Richter, Joshua, Rosenbaum, Cara, Patel, Dhwani, Smith, Eric, Korde, Neha, Lu, Sydney, Mailankody, Sham, Shah, Urvi, Lesokhin, Alexander, Hassoun, Hani, Tan, Carlyn, Maura, Francesco, Derkach, Andriy, Diamond, Benjamin, Rossi, Adriana, Pearse, Roger, Madduri, Deepu, Chari, Ajai, Kaminetzky, David, Braunstein, Marc, Gordillo, Christian, Reshef, Ran, Taur, Ying, Davies, Faith, Jagannath, Sundar, Niesvizky, Ruben, Lentzsch, Suzanne, Morgan, Gareth, and Landgren, Ola

Abstract

UNLABELLED: Patients with multiple myeloma have a compromised immune system, due to both the disease and antimyeloma therapies, and may therefore be particularly susceptible to COVID-19. Here, we report outcomes and risk factors for serious disease in patients with multiple myeloma treated at five large academic centers in New York City in the spring of 2020, during which it was a global epicenter of the SARS-CoV-2 pandemic. Of 100 patients with multiple myeloma (male 58%; median age 68) diagnosed with COVID-19, 75 were admitted; of these, 13 patients (17%) were placed on invasive mechanical ventilation, and 22 patients (29%) expired. Of the 25 nonadmitted patients, 4 were asymptomatic. There was a higher risk of adverse outcome (intensive care unit admission, mechanical ventilation, or death) in Hispanics/Latinos (n = 21), OR = 4.7 (95% confidence interval, 1.3-16.7), and African American Blacks (n = 33), OR = 3.5 (1.1-11.5), as compared with White patients (n = 36). Patients who met the adverse combined endpoint had overall higher levels of inflammatory markers and cytokine activation. None of the other studied risk factors were significantly associated (P > 0.05) with adverse outcome: hypertension (n = 56), OR = 2.2 (0.9-5.4); diabetes (n = 18), OR = 0.9 (0.3-2.9); age >65 years (n = 63), OR = 1.8 (0.7-4.6); high-dose melphalan with autologous stem cell transplant

Published
2020

7. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.

Author

Jakubowiak, Andrzej, Jasielec, Jagoda, Rosenbaum, Cara, Cole, Craig, Chari, Ajai, Mikhael, Joseph, Nam, Jennifer, McIver, Amanda, Severson, Erica, Stephens, Leonor, Tinari, Kathryn, Rosebeck, Shaun, Zimmerman, Todd, Hycner, Tyler, Turowski, Agata, Karrison, Theodore, and Zonder, Jeffrey

Subjects
carfilzomib, dexamethasone, relapsed/refractory multiple myeloma, selinexor, Aged, Antineoplastic Combined Chemotherapy Protocols, Cytogenetic Analysis, Dexamethasone, Drug Resistance, Neoplasm, Female, Humans, Hydrazines, Male, Middle Aged, Multiple Myeloma, Neoplasm Staging, Oligopeptides, Prognosis, Recurrence, Retreatment, Treatment Outcome, Triazoles
Abstract

Selinexor, an oral Selective Inhibitor of Nuclear Export, targets Exportin 1 (XPO1, also termed CRM1). Non-clinical studies support combining selinexor with proteasome inhibitors (PIs) and corticosteroids to overcome resistance in relapsed/refractory multiple myeloma (RRMM). We conducted a phase I dose-escalation trial of twice-weekly selinexor in combination with carfilzomib and dexamethasone (SKd) to determine maximum tolerated dose in patients with RRMM (N = 21), with an expansion cohort to assess activity in carfilzomib-refractory disease and identify a recommended phase II dose (RP2D). During dose escalation, there was one dose-limiting toxicity (cardiac failure). The RP2D of twice-weekly SKd was selinexor 60 mg, carfilzomib 20/27 mg/m2 and dexamethasone 20 mg. The most common grade 3/4 treatment-emergent adverse events included thrombocytopenia (71%), anaemia (33%), lymphopenia (33%), neutropenia (33%) and infections (24%). Rates of ≥minimal response, ≥partial response and very good partial response were 71%, 48% and 14%, respectively; similar response outcomes were observed for dual-class refractory (PI and immunomodulatory drug)/quad-exposed (carfilzomib, bortezomib, lenalidomide and pomalidomide) patients (n = 17), and patients refractory to carfilzomib in last line of therapy (n = 13). Median progression-free survival was 3·7 months, and overall survival was 22·4 months in the overall population. SKd was tolerable and re-established disease control in RRMM patients, including carfilzomib-refractory patients. Registered at ClinicalTrials.gov (NCT02199665).

Published
2019

8. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

Author

Dimopoulos, Meletios A, Richardson, Paul G, Bahlis, Nizar J, Grosicki, Sebastian, Cavo, Michele, Beksaç, Meral, Legieć, Wojciech, Liberati, Anna M, Goldschmidt, Hartmut, Belch, Andrew, Magen, Hila, Larocca, Alessandra, Laubach, Jacob P, Petrucci, Maria T, Reece, Donna, White, Darrell, Mateos, María-Victoria, Špička, Ivan, Lazaroiu, Mihaela, Berdeja, Jesús, Kaufman, Jonathan L, Jou, Ying-Ming, Ganetsky, Alex, Popa McKiver, Mihaela, Lonial, Sagar, Weisel, Katja, Sandhu, Irwindeep, Podhorecka, Monika, Palumbo, Antonio, Shacham-Abulafia, Adi, Vaxman, Iuliana, Shpilberg, Ofer, Besemer, Britta, Martelli, Maurizio, Foà, Roberto, De Fabritiis, Paolo, Caravita di Toritto, Tommaso, Gheorghita, Emanuil, Oriol, Albert, Rowlings, Philip, Emanuele, Angelucci, Carella, Angelo M, Offidani, Massimo, Bladé, Joan, Casado, Luis F, Oakervee, Heather, Panelli, Victoria, Meza, Luis, Kühr, Thomas, Granell, Miguel, Benson, Don, Nair, Rajesh, Holden, Viran, Reeves, James, Jr., Eek, Richard W, Walker, Patricia A, Catalano, John, Rosta, András, Lech-Marańda, Ewa, Samaras, Christy, Reiman, Anthony, Weaver, Robert, Acs, Peter, Grigg, Andrew, De Prijck, Bernard, Louzada, Martha, Minuk, Leonard, Sebag, Michael, Klausmann, Martine, Welslau, Manfred, Hellmann, Andrzej, Danaila, Catalin, Becker, Pamela, Bensinger, William, Porterfield, Bruce, Modiano, Manuel, Schultz, Stephen M, Manges, Robert, Lee, Huey-Shin Cindy, Gray, James X, Wright, Matthew P, Vekemans, Marie-Christine, Hamed, Aryan, Gasztonyi, Zoltán, Mikala, Gábor, Masszi, Tamás, Gamberi, Barbara, Kuliczkowski, Kazimierz, Usnarska-Zubkiewicz, Lidia, Bengoechea, Enrique, Gutiérrez, María AE, García, Miguel TH, San-Miguel, Jesús, Driessen, Christoph, Behl, Rajesh, Brenner, Warren, Gray, Carl, Hansen, Vincent, Moezi, Mehdi, Cortes, Hector V, Yen, Charles, Gressot, Laurent, Horvath, Noemi, D'Rozario, James M, Latimer, Maya, Kyrtsonis, Maria-Christine, Chubar, Evgeni, Mittelman, Moshe, Baldini, Luca, Tosi, Patrizia, Vacca, Angelo, Jędrzejczak, Wiesław W, Robak, Tadeusz, Lahuerta, Juan J, Carney, Jennifer, Chen, Franklin, Hirsch, Robert, Ruiz, Marco, Alencar, Alvaro, Jagasia, Madan, Kasbari, Samer, Kuriakose, Philip, Mahmood, Aftab, Chaudhry, Madhu, Cohen, Gary, Noga, Stephen, Roa, Sch, Jakubowiak, Andrzej, Rosenbaum, Cara, Delforge, Michel, Delrieu, Vanessa, Doyen, Chantal, Dries, Deeren, Demuynck, Hilde, Schots, Rik, Maisnar, Vladimir, Blau, Igor W, Dürk, Heinz A, Kerkhoff, Andrea, Kropff, Martin, Munder, Markus, Röllig, Christoph, Scheid, Christof, Symeonidis, Argiris S, Illés, Árpád, Coyne, Mark, O'Gorman, Peter, Hayden, Patrick, O'Dwyer, Michael, Ben-Yehuda, Dina, Braester, Andrei, Nemets, Anatoly, Lugassy, Gilles, Cohen, Yossi, Rahimi-Levene, Naomi, Bosi, Alberto, Pezzatti, Sara, Rossini, Fausto, Pogliani, Enrico M, Pinto, Antonello, Komarnicki, Mieczysław, Borsaru, Gabriela, Stoia, Razvan, Afanasyev, Boris, Goñi, María A, Carboneras, Ana V, Ali, Sarah, Rubenstein, S. Eric, Caputto, Salvador, Cosgriff, Thomas, Fanning, Suzanne, Khojasteh, Ali, Liman, Andrew, Malcolm, Albert, Vrindavanam, Nandagopal, Patel, Ravindranath, Belani, Rajesh, Shieh, Marie, Stockerl-Goldstein, Keith, Strnad, Charles, Stuart, Robert, Chhabra, Saurabh, Costa, Luciano, Jhangiani, Haresh, Augustson, Bradley, Filshie, Robin, Johnston, Amanda, Hertzberg, Mark S, Mineur, Philippe, Fox, Susan, Kotb, Rami, Dao, Vi, LeBlanc, Richard, Gregora, Evzen, Brioli, Annamaria, Mügge, Lars-Olof, Hänel, Mathias, Langer, Christian, Kapsali, Eleni, Briasoulis, Evangelos, Kyriakou, Despoina, Hardan, Izhar, Horowitz, Netanel A, Clotilde, Cangialosi, Fabbiano, Francesco, Castagnari, Barbara, Ciceri, Fabio, Musuraca, Gerardo, Deptała, Andrzej, Kłoczko, Janusz, Balea, Marius, Vladareanu, Ana-Maria, Rossiev, Victor, Alegre, Adrián, Encinas, Cristina, Gayoso, Jorge, Pabst, Thomas, Rabin, Neil, Arledge, Sherri, Cabanillas, Fernando, Catlett, Joseph, Chidiac, Tarek, Clarkson, David, Dhodapkar, Madhav, Geils, George, Jr., Khan, Cyrus MA, Sahovic, Entezam, Khasawneh, Mohamad, Sehgal, Rajesh, Ballester, Oscar, Levy, Moshe, Fay, Joseph, Liem, Kiem, Lunning, Matthew, Vose, Julie, Faber, Edward, Jr., MacFarlane, Donald, Hohl, Raymond, Mahmood, Tariq, Bhaskar, Birbal, Mims, Martha, Oliff, Ira, Paner, Agne, Maciejewski, John, Padmanabhan, Arvinda, Richard, Robert, Sanyal, Amit, Schiller, Gary, Staszewski, Harry, Stevens, Don, Vaughn, Christopher, and Windsor, Kevin

Published
2022
Full Text
View/download PDF

9. A pipeline for malignancy and therapy agnostic assessment of cancer drug response using cell mass measurements

Author

Kimmerling, Robert J., Stevens, Mark M., Olcum, Selim, Minnah, Anthony, Vacha, Madeleine, LaBella, Rachel, Ferri, Matthew, Wasserman, Steven C., Fujii, Juanita, Shaheen, Zayna, Sundaresan, Srividya, Ribadeneyra, Drew, Jayabalan, David S., Agte, Sarita, Aleman, Adolfo, Criscitiello, Joseph A., Niesvizky, Ruben, Luskin, Marlise R., Parekh, Samir, Rosenbaum, Cara A., Tamrazi, Anobel, and Reid, Clifford A.

Published
2022
Full Text
View/download PDF

10. Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma.

Author

Richardson, Paul, Hofmeister, Craig, Rosenbaum, Cara, Htut, Myo, Vesole, David, Berdeja, Jesus, Liedtke, Michaela, Chari, Ajai, Smith, Stephen, Lebovic, Daniel, Raje, Noopur, Byrne, Catriona, Liao, Eileen, Gupta, Neeraj, Bacco, Alessandra, Estevam, Jose, Berg, Deborah, and Baz, Rachid

Subjects
ixazomib, multiple myeloma, newly diagnosed, oral, twice-weekly, Administration, Oral, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Boron Compounds, Dexamethasone, Disease-Free Survival, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Glycine, Humans, Lenalidomide, Male, Middle Aged, Multiple Myeloma, Treatment Outcome
Abstract

Weekly ixazomib with lenalidomide-dexamethasone (Rd) is feasible and has shown activity in newly diagnosed multiple myeloma (NDMM) patients. This phase 1/2 study (NCT01383928) evaluated the recommended phase 2 dose (RP2D), pharmacokinetics, safety and efficacy of twice-weekly ixazomib plus Rd in NDMM; 64 patients were enrolled across both phases. Patients received twice-weekly oral ixazomib 3·0 or 3·7 mg plus lenalidomide 25 mg and dexamethasone 20 mg (10 mg in cycles 9-16) for up to sixteen 21-day cycles, followed by maintenance with twice-weekly ixazomib alone. No dose-limiting toxicities were reported in cycle 1; the RP2D was 3·0 mg based on overall tolerability across multiple cycles. In 62 evaluable patients, the confirmed overall response rate was 94% (68% ≥very good partial response; 24% complete response). Median progression-free survival was 24·9 months. Responses (median duration 36·9 months for patients receiving the RP2D) deepened during treatment. Grade 3 drug-related adverse events (AEs) occurred in 64% of patients, including: rash, 13%; peripheral neuropathy, 8%; hyperglycaemia, 8%. There were no grade 4 drug-related AEs. Thirteen patients discontinued due to AEs. Twice-weekly ixazomib-Rd offers substantial activity with promising long-term outcomes in NDMM patients but may be associated with greater toxicity compared with weekly ixazomib-Rd in this setting.

Published
2018

11. Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group

Author

Havasi, Andrea, Heybeli, Cihan, Leung, Nelson, Angel-Korman, Avital, Sanchorawala, Vaishali, Cohen, Oliver, Wechalekar, Ashutosh, Bridoux, Frank, Jaffer, Insara, Gutgarts, Victoria, Hassoun, Hani, Levinson, Maya, Rosenbaum, Cara, Milani, Paolo, Palladini, Giovanni, Merlini, Giampaolo, Hegenbart, Ute, Schönland, Stefan, Veelken, Kaya, Pogrebinsky, Alexander, Doros, Gheorghe, and Landau, Heather

Published
2022
Full Text
View/download PDF

12. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

Author

Chari, Ajai, Samur, Mehmet Kemal, Martinez-Lopez, Joaquin, Cook, Gordon, Biran, Noa, Yong, Kwee, Hungria, Vania, Engelhardt, Monika, Gay, Francesca, García Feria, Ana, Oliva, Stefania, Oostvogels, Rimke, Gozzetti, Alessandro, Rosenbaum, Cara, Kumar, Shaji, Stadtmauer, Edward A., Einsele, Hermann, Beksac, Meral, Weisel, Katja, Anderson, Kenneth C., Mateos, María-Victoria, Moreau, Philippe, San-Miguel, Jesus, Munshi, Nikhil C., and Avet-Loiseau, Hervé

Published
2020
Full Text
View/download PDF

13. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma

Author

Jasielec, Jagoda K., Kubicki, Tadeusz, Raje, Noopur, Vij, Ravi, Reece, Donna, Berdeja, Jesus, Derman, Benjamin A., Rosenbaum, Cara A., Richardson, Paul, Gurbuxani, Sandeep, Major, Sarah, Wolfe, Brittany, Stefka, Andrew T., Stephens, Leonor, Tinari, Kathryn M., Hycner, Tyler, Rojek, Alexandra E., Dytfeld, Dominik, Griffith, Kent A., Zimmerman, Todd M., and Jakubowiak, Andrzej J.

Published
2020
Full Text
View/download PDF

15. Impact of Imaging Frequency on Progression Free Survival in Alliance Trials Enrolling Patients with Follicular Lymphoma

Author

Rutherford, Sarah C., primary, Yin, Jun, additional, Pederson, Levi D., additional, Blum, Kristie A., additional, Martin, Peter, additional, Jung, Sin-Ho, additional, Grant, Barbara, additional, Rosenbaum, Cara A, additional, Cheson, Bruce David, additional, Bartlett, Nancy L., additional, Mandrekar, Sumithra J, additional, and Leonard, John P., additional

Published
2024
Full Text
View/download PDF

16. Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis

Author

Gertz, Morie, primary, Abonour, Rafat, additional, Gibbs, Sarah, additional, Finkel, Muriel, additional, Landau, Heather, additional, Lentzsch, Suzanne, additional, Lin, Grace, additional, Mahindra, Anuj, additional, Quock, Tiffany, additional, Rosenbaum, Cara, additional, Rosenzweig, Michael, additional, Sidana, Surbhi, additional, Tuchman, Sascha, additional, Witteles, Ronald, additional, Yermilov, Irina, additional, and Broder, Michael, additional

Published
2023
Full Text
View/download PDF

19. Data from COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers

Author

Hultcrantz, Malin, primary, Richter, Joshua, primary, Rosenbaum, Cara A., primary, Patel, Dhwani, primary, Smith, Eric L., primary, Korde, Neha, primary, Lu, Sydney X., primary, Mailankody, Sham, primary, Shah, Urvi A., primary, Lesokhin, Alexander M., primary, Hassoun, Hani, primary, Tan, Carlyn, primary, Maura, Francesco, primary, Derkach, Andriy, primary, Diamond, Benjamin, primary, Rossi, Adriana, primary, Pearse, Roger N., primary, Madduri, Deepu, primary, Chari, Ajai, primary, Kaminetzky, David, primary, Braunstein, Marc J., primary, Gordillo, Christian, primary, Reshef, Ran, primary, Taur, Ying, primary, Davies, Faith E., primary, Jagannath, Sundar, primary, Niesvizky, Ruben, primary, Lentzsch, Suzanne, primary, Morgan, Gareth J., primary, and Landgren, Ola, primary

Published
2023
Full Text
View/download PDF

20. SupplementaryTable1.xlsx from COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers

Author

Hultcrantz, Malin, primary, Richter, Joshua, primary, Rosenbaum, Cara A., primary, Patel, Dhwani, primary, Smith, Eric L., primary, Korde, Neha, primary, Lu, Sydney X., primary, Mailankody, Sham, primary, Shah, Urvi A., primary, Lesokhin, Alexander M., primary, Hassoun, Hani, primary, Tan, Carlyn, primary, Maura, Francesco, primary, Derkach, Andriy, primary, Diamond, Benjamin, primary, Rossi, Adriana, primary, Pearse, Roger N., primary, Madduri, Deepu, primary, Chari, Ajai, primary, Kaminetzky, David, primary, Braunstein, Marc J., primary, Gordillo, Christian, primary, Reshef, Ran, primary, Taur, Ying, primary, Davies, Faith E., primary, Jagannath, Sundar, primary, Niesvizky, Ruben, primary, Lentzsch, Suzanne, primary, Morgan, Gareth J., primary, and Landgren, Ola, primary

Published
2023
Full Text
View/download PDF

22. Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis

Author

Gertz,Morie, Abonour,Rafat, Gibbs,Sarah, Finkel,Muriel, Landau,Heather, Lentzsch,Suzanne, Lin,Grace, Mahindra,Anuj, Quock,Tiffany, Rosenbaum,Cara, Rosenzweig,Michael, Sidana,Surbhi, Tuchman,Sascha, Witteles,Ronald, Yermilov,Irina, Broder,Michael, Gertz,Morie, Abonour,Rafat, Gibbs,Sarah, Finkel,Muriel, Landau,Heather, Lentzsch,Suzanne, Lin,Grace, Mahindra,Anuj, Quock,Tiffany, Rosenbaum,Cara, Rosenzweig,Michael, Sidana,Surbhi, Tuchman,Sascha, Witteles,Ronald, Yermilov,Irina, and Broder,Michael

Abstract

Morie Gertz,1,* Rafat Abonour,2,* Sarah N Gibbs,3,* Muriel Finkel,4,* Heather Landau,5,* Suzanne Lentzsch,6,* Grace Lin,7,* Anuj Mahindra,8,* Tiffany Quock,9,* Cara Rosenbaum,10,* Michael Rosenzweig,11,* Surbhi Sidana,12,* Sascha A Tuchman,13,* Ronald Witteles,12,* Irina Yermilov,3,* Michael S Broder3,* 1Department of Medicine, Mayo Clinic, Rochester, MN, USA; 2Department of Medicine, Indiana University School of Medicine; Director, Multiple Myeloma, Waldenstrom’s Disease and Amyloidosis Program, Indianapolis, IN, USA; 3PHAR (Partnership for Health Analytic Research), Beverly Hills, CA, USA; 4Amyloidosis Support Groups Inc, Wood Dale, IL, USA; 5Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 6Multiple Myeloma and Amyloidosis Program, Columbia University Medical Center, New York, NY, USA; 7Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA; 8Malignant Hematology, Scripps Clinic MD Anderson Cancer Center, La Jolla, CA, USA; 9Health Economics and Outcomes Research, Prothena Biosciences Ltd., South San Francisco, CA, USA; 10Department of Medicine, Hematology/Oncology, Weill Cornell Medical College, New York, NY, USA; 11Division of Multiple Myeloma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA; 12Division of Cardiovascular Medicine, Stanford School of Medicine, Palo Alto, CA, USA; 13Division of Hematology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA*These authors contributed equally to this workCorrespondence: Michael S Broder, PHAR (Partnership for Health Analytic Research), 280 S Beverly Drive, Suite 404, Beverly Hills, CA, 90212, USA, Tel +1 310 858 9555, Email mbroder@pharllc.comPurpose: Patients with diagnosed with systemic light chain (AL) amyloidosis at advanced Mayo stages have greater morbidity and mo

Published
2023

23. Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials

Author

Rutherford, Sarah C., primary, Yin, Jun, additional, Pederson, Levi, additional, Perez Burbano, Gabriela, additional, LaPlant, Betsy, additional, Shadman, Mazyar, additional, Li, Hongli, additional, LeBlanc, Michael L., additional, Kenkre, Vaishalee P., additional, Hong, Fangxin, additional, Blum, Kristie A., additional, Dockter, Travis, additional, Martin, Peter, additional, Jung, Sin-Ho, additional, Grant, Barbara, additional, Rosenbaum, Cara, additional, Ujjani, Chaitra, additional, Barr, Paul M., additional, Unger, Joseph M., additional, Cheson, Bruce D., additional, Bartlett, Nancy L., additional, Kahl, Brad, additional, Friedberg, Jonathan W., additional, Mandrekar, Sumithra J., additional, and Leonard, John P., additional

Published
2023
Full Text
View/download PDF

25. Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial

Author

Kumar, Shaji K, primary, Alsina, Melissa, additional, Laplant, Betsy, additional, Badros, Ashraf Z., additional, Abdallah, Al-Ola, additional, Abonour, Rafat, additional, Asmus, Erik J, additional, Dhakal, Binod, additional, Rosenbaum, Cara A., additional, Egan, Daniel, additional, Bhutani, Manisha, additional, Jakubowiak, Andrzej, additional, and Durie, Brian G.M., additional

Published
2022
Full Text
View/download PDF

27. Healthcare Utilization Among Patients with Advanced Systemic Light Chain Amyloidosis

Author

Gertz, Morie A., primary, Abonour, Rafat, additional, Gibbs, Sarah N., additional, Finkel, Muriel, additional, Landau, Heather, additional, Lentzsch, Suzanne, additional, Lin, Grace, additional, Mahindra, Anuj, additional, Quock, Tiffany P., additional, Rosenbaum, Cara A., additional, Rosenzweig, Michael, additional, Sidana, Surbhi, additional, Tuchman, Sascha A., additional, Witteles, Ronald, additional, Yermilov, Irina, additional, and Broder, Michael S., additional

Published
2022
Full Text
View/download PDF

30. First report of outcomes in patients with stage IIIb AL amyloidosis treated with Dara–VCD front‐line therapy.

Author

Chakraborty, Rajshekhar, Rosenbaum, Cara, Kaur, Gurbakhash, Bhutani, Divaya, Radhakrishnan, Jai, Mapara, Markus Y., Maurer, Mathew, and Lentzsch, Suzanne

Subjects
*CARDIAC amyloidosis, *IMMUNOGLOBULIN light chains, *AMYLOIDOSIS, *TREATMENT effectiveness
Abstract

Summary: Although Dara–VCD (daratumumab–bortezomib–cyclophosphamide–dexamethasone) has revolutionized the treatment of newly diagnosed Amyloid Light chain (AL) amyloidosis, patients with stage IIIb disease were excluded in the pivotal trial. We performed a multicentre retrospective cohort study to investigate the outcomes of 19 consecutive patients treated with Dara–VCD front‐line therapy who had stage IIIb AL at diagnosis. More than two thirds presented with New York Heart Association Class III/IV symptoms, and had a median of two organs involved (range, 2–4). The haematologic overall response rate was 100%, with 17/19 patients (89.5%) achieving a very good partial response (VGPR) or better. Haematologic responses were achieved rapidly, as evidenced by 63% of evaluable patients with involved serum free light chains (iFLC) < 2 mg/dl and the difference between involved and uninvolved serum free light chains (dFLC) <1 mg/dl at three months. Among 18 evaluable patients, 10 (56%) achieved a cardiac organ response and six (33%) cardiac VGPR or better. The median time to first cardiac response was 1.9 months (range, 0.4–7.3). At a median follow‐up of 12 months for surviving patients, estimated one‐year overall survival was 67.5% [95% confidence interval (CI), 43.8–84.7]. The incidence of grade 3 or higher infections was 21%, with no infection‐related mortality thus far. In summary, Dara–VCD has a promising efficacy and safety profile in stage IIIb AL, and should be studied in prospective trials. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

31. Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma

Author

Lonial, Sagar, primary, Tarantolo, Stefano R., additional, Boccia, Ralph V., additional, Yimer, Habte, additional, Levy, Moshe Y., additional, Abonour, Rafat, additional, Mohan, Meera, additional, Roy, Vivek, additional, Larsen, Jeremy T., additional, Girnius, Saulius K., additional, Rosenbaum, Cara A., additional, Nadeem, Omar, additional, Berg, Deborah, additional, Chao, Bo, additional, Berger, Allison J, additional, Nakamura, Akito, additional, Zhang, Yuhong, additional, Song, Keli, additional, Ward, Christine K., additional, Proscurshim, Igor, additional, and Kumar, Shaji, additional

Published
2021
Full Text
View/download PDF

35. Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial

Author

Biran, Noa, primary, Dhakal, Binod, additional, Lentzsch, Suzanne, additional, Siegel, David, additional, Usmani, Saad Z., additional, Rossi, Adriana, additional, Rosenbaum, Cara, additional, Bhutani, Divaya, additional, Vesole, David H., additional, Rodriguez, Cesar, additional, Nooka, Ajay K., additional, van Rhee, Frits, additional, Stork‐Sloots, Lisette, additional, de Snoo, Femke, additional, Bhattacharyya, Pritish K., additional, Dash, Durga Prasad, additional, Zümrütçü, Sena, additional, van Vliet, Martin H., additional, Hari, Parameswaran, additional, and Niesvizky, Ruben, additional

Published
2021
Full Text
View/download PDF

36. Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society Dataset

Author

Chari, Ajai, Samur, Mehmet Kemal, Martinez-Lopez, Joaquin, Cook, Gordon, Biran, Noa, Yong, Kwee L., Hungria, Vania Tietsche de Moraes, Engelhardt, Monika, Gay, Francesca, Garcia-Feria, Ana, Oliva, Stefania, Oostvogels, Rimke, Gozzetti, Alessandro, Rosenbaum, Cara A, Kumar, Shaji K, Stadtmauer, Edward, Einsele, Hermann, Beksac, Meral, Weisel, Katja C, Anderson, Kenneth C, Mateos, Maria-Victoria, Moreau, Philippe, San Miguel, Jesús, Munshi, Nikhil C, and Avet-Loiseau, Hervé

Published
2020

37. Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set

Author

MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Chari, Ajai, Samur, Mehmet Kemal, Martinez-Lopez, Joaquin, Cook, Gordon, Biran, Noa, Yong, Kwee, Hungria, Vania, Engelhardt, Monika, Gay, Francesca, Feria, Ana García, Oliva, Stefania, Oostvogels, Rimke, Gozzetti, Alessandro, Rosenbaum, Cara, Kumar, Shaji, Stadtmauer, Edward A., Einsele, Hermann, Beksac, Meral, Weisel, Katja, Anderson, Kenneth C., Mateos, María Victoria, Moreau, Philippe, San-Miguel, Jesus, Munshi, Nikhil C., Avet-Loiseau, Hervé, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Chari, Ajai, Samur, Mehmet Kemal, Martinez-Lopez, Joaquin, Cook, Gordon, Biran, Noa, Yong, Kwee, Hungria, Vania, Engelhardt, Monika, Gay, Francesca, Feria, Ana García, Oliva, Stefania, Oostvogels, Rimke, Gozzetti, Alessandro, Rosenbaum, Cara, Kumar, Shaji, Stadtmauer, Edward A., Einsele, Hermann, Beksac, Meral, Weisel, Katja, Anderson, Kenneth C., Mateos, María Victoria, Moreau, Philippe, San-Miguel, Jesus, Munshi, Nikhil C., and Avet-Loiseau, Hervé

Published
2020

38. Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

Author

McCarthy, Philip L., Owzar, Kouros, Hofmeister, Craig C., Hurd, David D., Hassoun, Hani, Richardson, Paul G., Giralt, Sergio, Stadtmauer, Edward A., Weisdorf, Daniel J., Vij, Ravi, Moreb, Jan S., Callander, Natalie Scott, Van Besien, Koen, Gentile, Teresa, Isola, Luis, Maziarz, Richard T., Gabriel, Don A., Bashey, Asad, Landau, Heather, Martin, Thomas, Qazilbash, Muzaffar H., Levitan, Denise, McClune, Brian, Schlossman, Robert, Hars, Vera, Postiglione, John, Jiang, Chen, Bennett, Elizabeth, Barry, Susan, Bressler, Linda, Kelly, Michael, Seiler, Michele, Rosenbaum, Cara, Hari, Parameswaran, Pasquini, Marcelo C., Horowitz, Mary M., Shea, Thomas C., Devine, Steven M., Anderson, Kenneth C., and Linker, Charles

Published
2012
Full Text
View/download PDF

39. Timing of Daratumumab Administered Pre-Mobilization in Multiple Myeloma Impacts Pre-Harvest Peripheral Blood CD34+ Cell Counts and Plerixafor Use

Author

Luan, Danny, primary, Christos, Paul J, additional, Ancharski, Michael, additional, Guarneri, Danielle, additional, Pearse, Roger, additional, Rossi, Adriana C, additional, Shore, Tsiporah B., additional, Mayer, Sebastian, additional, Phillips, Adrienne A., additional, Hsu, Jingmei, additional, Vasovic, Ljiljana V., additional, Hsu, Yen-Michael S., additional, van Besien, Koen, additional, Niesvizky, Ruben, additional, and Rosenbaum, Cara A., additional

Published
2020
Full Text
View/download PDF

40. Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma (SMM): Initial Analysis of Safety Data

Author

Kumar, Shaji K., primary, Abdallah, Al-Ola, additional, Badros, Ashraf Z., additional, Laplant, Betsy, additional, Dhakal, Binod, additional, Alsina, Melissa, additional, Abonour, Rafat, additional, Rosenbaum, Cara A., additional, Bensinger, William I, additional, Bhutani, Manisha, additional, Jakubowiak, Andrzej, additional, Kim, Erica, additional, and Durie, Brian G.M., additional

Published
2020
Full Text
View/download PDF

41. Correction: COVID-19 Infections and Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers

Author

Hultcrantz, Malin, primary, Richter, Joshua, additional, Rosenbaum, Cara A., additional, Patel, Dhwani, additional, Smith, Eric L., additional, Korde, Neha, additional, Lu, Sydney X., additional, Mailankody, Sham, additional, Shah, Urvi A., additional, Lesokhin, Alexander M., additional, Hassoun, Hani, additional, Tan, Carlyn, additional, Maura, Francesco, additional, Derkach, Andriy, additional, Diamond, Benjamin, additional, Rossi, Adriana, additional, Pearse, Roger, additional, Madduri, Deepu, additional, Chari, Ajai, additional, Kaminetzky, David, additional, Braunstein, Marc J., additional, Gordillo, Christian, additional, Reshef, Ran, additional, Taur, Ying, additional, Davies, Faith E., additional, Jagannath, Sundar, additional, Niesvizky, Ruben, additional, Lentzsch, Suzanne, additional, Morgan, Gareth J., additional, and Landgren, Ola, additional

Published
2020
Full Text
View/download PDF

42. COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers

Author

Hultcrantz, Malin, primary, Richter, Joshua, additional, Rosenbaum, Cara A., additional, Patel, Dhwani, additional, Smith, Eric L., additional, Korde, Neha, additional, Lu, Sydney X., additional, Mailankody, Sham, additional, Shah, Urvi A., additional, Lesokhin, Alexander M., additional, Hassoun, Hani, additional, Tan, Carlyn, additional, Maura, Francesco, additional, Derkach, Andriy, additional, Diamond, Benjamin, additional, Rossi, Adriana, additional, Pearse, Roger N., additional, Madduri, Deepu, additional, Chari, Ajai, additional, Kaminetzky, David, additional, Braunstein, Marc J., additional, Gordillo, Christian, additional, Reshef, Ran, additional, Taur, Ying, additional, Davies, Faith E., additional, Jagannath, Sundar, additional, Niesvizky, Ruben, additional, Lentzsch, Suzanne, additional, Morgan, Gareth J., additional, and Landgren, Ola, additional

Published
2020
Full Text
View/download PDF

43. Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society COVID-19 Dataset

Author

Chari, Ajai, primary, Samur, Mehmet Kemal, additional, Martinez-Lopez, Joaquin, additional, Cook, Gordon, additional, Biran, Noa, additional, Yong, Kwee, additional, Hungria, Vania, additional, Engelhardt, Monika, additional, Gay, Francesca, additional, Feria, Ana García, additional, Oliva, Stefania, additional, Oostvogels, Rimke, additional, Gozzetti, Alessandro, additional, Rosenbaum, Cara, additional, Kumar, Shaji, additional, Stadtmauer, Edward A., additional, Einsele, Hermann, additional, Beksac, Meral, additional, Weisel, Katja, additional, Anderson, Kenneth C., additional, Mateos, María-Victoria, additional, Moreau, Philippe, additional, San-Miguel, Jesus, additional, Munshi, Nikhil C., additional, and Avet-Loiseau, Hervé, additional

Published
2020
Full Text
View/download PDF

44. Plasma Cell Myeloma Presenting With Amyloid-Laden Crystal-Negative Histiocytosis

Author

Braunstein, Marc J, primary, Petrova-Drus, Kseniya, additional, Rosenbaum, Cara A, additional, Jayabalan, David S, additional, Rossi, Adriana C, additional, Salvatore, Steven, additional, Rech, Karen, additional, Pearse, Roger N, additional, Hassane, Duane C, additional, Postley, John, additional, Jhanwar, Yuliya S, additional, Geyer, Julia T, additional, and Niesvizky, Ruben, additional

Published
2020
Full Text
View/download PDF

46. COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers

Author

Hultcrantz, Malin, primary, Richter, Joshua, additional, Rosenbaum, Cara, additional, Patel, Dhwani, additional, Smith, Eric, additional, Korde, Neha, additional, Lu, Sydney, additional, Mailankody, Sham, additional, Shah, Urvi, additional, Lesokhin, Alexander, additional, Hassoun, Hani, additional, Tan, Carlyn, additional, Maura, Francesco, additional, Derkacs, Andriy, additional, Diamond, Benjamin, additional, Rossi, Adriana, additional, Pearse, Roger N., additional, Madduri, Deepu, additional, Chari, Ajai, additional, Kaminetsky, David, additional, Braunstein, Marc, additional, Gordillo, Christian, additional, Davies, Faith, additional, Jagannath, Sundar, additional, Niesvizky, Ruben, additional, Lentzsch, Suzanne, additional, Morgan, Gareth, additional, and Landgren, Ola, additional

Published
2020
Full Text
View/download PDF

47. Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials.

Author

Rutherford, Sarah C., primary, Yin, Jun, additional, Pederson, Levi, additional, LaPlant, Betsy, additional, Shadman, Mazyar, additional, Li, Hongli, additional, LeBlanc, Michael Leo, additional, Blum, Kristie A., additional, Dockter, Travis, additional, Martin, Peter, additional, Jung, Sin-Ho, additional, Grant, Barbara W., additional, Rosenbaum, Cara Ann, additional, Ujjani, Chaitra Shankar, additional, Barr, Paul M., additional, Unger, Joseph M., additional, Cheson, Bruce D., additional, Bartlett, Nancy L., additional, Friedberg, Jonathan W., additional, and Leonard, John Paul, additional

Published
2020
Full Text
View/download PDF

48. SKY92 Impacts Treatment Plan in Newly Diagnosed Multiple Myeloma Patients in the Prospective PROMMIS Trial

Author

Biran, Noa, primary, Dhakal, Binod, additional, Lentzsch, Suzanne, additional, Siegel, David, additional, Usmani, Saad Z., additional, Rossi, Adriana, additional, Rosenbaum, Cara, additional, Bhutani, Divaya, additional, Vesole, David H., additional, Rodriguez, Cesar, additional, Nooka, Ajay K., additional, van Rhee, Frits, additional, Stork-Sloots, Lisette, additional, de Snoo, Femke, additional, Bhattacharyya, Pritish K., additional, Dash, DP, additional, Zümrütçü, Sena, additional, van Vliet, Martin, additional, Hari, Parameswaran, additional, and Niesvizky, Ruben, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results